ID27787A - COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES - Google Patents

COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES

Info

Publication number
ID27787A
ID27787A IDW20010428A ID20010428A ID27787A ID 27787 A ID27787 A ID 27787A ID W20010428 A IDW20010428 A ID W20010428A ID 20010428 A ID20010428 A ID 20010428A ID 27787 A ID27787 A ID 27787A
Authority
ID
Indonesia
Prior art keywords
viruses
prevention
compound
treatment
composition
Prior art date
Application number
IDW20010428A
Other languages
Indonesian (id)
Inventor
Thomas R Bailey
Dorothy C Young
Original Assignee
Viro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viro Pharma Inc filed Critical Viro Pharma Inc
Publication of ID27787A publication Critical patent/ID27787A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
IDW20010428A 1998-08-21 1999-08-19 COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES ID27787A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9747698P 1998-08-21 1998-08-21
US11321298P 1998-12-22 1998-12-22
US11932899P 1999-02-09 1999-02-09
US13558699P 1999-05-24 1999-05-24
US13558599P 1999-05-24 1999-05-24

Publications (1)

Publication Number Publication Date
ID27787A true ID27787A (en) 2001-04-26

Family

ID=27536838

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010428A ID27787A (en) 1998-08-21 1999-08-19 COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES

Country Status (10)

Country Link
EP (1) EP1128832A4 (en)
JP (1) JP2002523371A (en)
KR (1) KR20010099623A (en)
CN (1) CN1325309A (en)
AU (1) AU743411B2 (en)
BR (1) BR9913157A (en)
CA (1) CA2341970A1 (en)
ID (1) ID27787A (en)
IL (1) IL141456A0 (en)
WO (1) WO2000010573A1 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003502320A (en) * 1999-06-10 2003-01-21 ワーナー−ランバート・カンパニー Rhodanin derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
AU2001253206A1 (en) * 2000-04-05 2001-10-23 Tularik, Inc. Ns5b hcv polymerase inhibitors
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
YU23503A (en) * 2000-09-29 2006-03-03 Neurogen Corporation High afinity small molecule c5a receptor modulators
AU2002252227A1 (en) 2001-03-07 2002-09-24 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
WO2002072543A2 (en) 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Rxr activating molecules
GB2376944A (en) * 2001-05-18 2002-12-31 Pantherix Ltd Polycyclic heterocyclic compounds and their therapeutic use
JP4558314B2 (en) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド Viral polymerase inhibitor
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US20030134853A1 (en) 2001-09-26 2003-07-17 Priestley Eldon Scott Compounds useful for treating hepatitis C virus
JP2005513026A (en) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド Hypercholesterolemia, dyslipidemia and other metabolic disorders; N-substituted heterocycles to treat cancer and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
CA2486138A1 (en) * 2002-05-17 2003-11-27 Qlt Inc. Methods of using thiazolidinedithione derivatives
EP1506172B1 (en) 2002-05-20 2011-03-30 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US6878722B2 (en) 2002-05-20 2005-04-12 Bristol-Myers Squibb Company Substituted cycloalkyl P1′ hepatitis C virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2003099316A1 (en) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
US20040142993A1 (en) 2002-07-01 2004-07-22 Carlo Battistini Inhibitors of HCV NS5B polymerase
BR0305426A (en) 2002-07-01 2004-08-24 Upjohn Co Hsv ns5b polymerase inhibitor compounds as well as pharmaceutical composition comprising the same
FR2845000B1 (en) * 2002-09-27 2005-05-27 Oreal USE OF A HETEROCYCLIC COMPOUND OR ONE OF ITS SALTS FOR STIMULATING OR INDUCING THE GROWTH OF HAIR AND / OR BRAKING THEIR FALL
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
AP2005003292A0 (en) * 2002-09-30 2005-06-30 Univ California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2004043955A1 (en) * 2002-11-13 2004-05-27 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
ATE422895T1 (en) 2003-04-16 2009-03-15 Bristol Myers Squibb Co MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS
DE602004025708D1 (en) 2003-07-11 2010-04-08 Proteologics Inc UBIQUITIN LIGASE INHIBITORS AND RELATED METHODS
FR2858324A1 (en) * 2003-07-30 2005-02-04 Centre Nat Rech Scient Composition used for treating microbial infections, effective particularly against rifampicin-resistant bacteria, contain new or known 5-(heterocyclylmethylene)-thiazolidine derivatives
US7112601B2 (en) 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
US7566732B2 (en) 2003-10-28 2009-07-28 Rigel Pharmaceuticals, Inc. Rhodanine compositions for use as antiviral agents
US7026339B2 (en) 2003-11-07 2006-04-11 Fan Yang Inhibitors of HCV NS5B polymerase
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG150511A1 (en) 2004-02-20 2009-03-30 Boehringer Ingelheim Int Viral polymerase inhibitors
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
RS50815B (en) 2004-02-24 2010-08-31 Japan Tobacco Inc. Fused heterotetracyclic compunds and use thereof as hcv polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
EP1879885A1 (en) 2005-05-04 2008-01-23 F. Hoffmann-Roche AG Heterocyclic antiviral compounds
US20060287319A1 (en) * 2005-06-15 2006-12-21 Shibo Jiang Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
WO2007131168A2 (en) * 2006-05-04 2007-11-15 Institute For Hepatitis And Virus Research Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
JP2010505902A (en) 2006-10-10 2010-02-25 メディヴィル・アクチエボラーグ HCV nucleoside inhibitors
WO2008082537A2 (en) * 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
EP2162432A2 (en) 2007-06-29 2010-03-17 Gilead Sciences, Inc. Antiviral compounds
KR101596524B1 (en) 2007-06-29 2016-02-22 길리애드 사이언시즈, 인코포레이티드 Antiviral compound
EP2217573A4 (en) * 2007-11-01 2011-08-31 Uab Research Foundation Treating and preventing viral infections
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US7947717B2 (en) 2008-07-18 2011-05-24 Burnham Institute For Medical Research Inhibitors of lethal factor protease
EA201190007A1 (en) 2008-12-03 2012-06-29 Пресидио Фармасьютикалс, Инк. HCV NS5A INHIBITORS
BRPI0922366B8 (en) 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc compound, pharmaceutical composition and use of a compound
CA2755658A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
CA2780044A1 (en) 2009-11-14 2011-05-19 F. Hoffmann-La Roche Ag Biomarkers for predicting rapid response to hcv treatment
EP2507636A1 (en) 2009-12-02 2012-10-10 F. Hoffmann-La Roche AG Biomarkers for predicting sustained response to hcv treatment
WO2011075784A1 (en) * 2009-12-23 2011-06-30 Peter Maccallum Cancer Institute Compounds, preparations and uses thereof
US8877707B2 (en) 2010-05-24 2014-11-04 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
KR101159000B1 (en) 2010-06-18 2012-06-21 (주) 에빅스젠 Novel rhodanine derivative, process for preparing the same and pharmaceutical composition for preventing or treating AIDS comprising the same
US9023876B2 (en) 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
US9255088B2 (en) 2010-08-11 2016-02-09 The Regents Of The University Of California Premature-termination-codons readthrough compounds
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
US9180193B2 (en) 2011-10-10 2015-11-10 Hoffmann-La Roche Inc. Antiviral compounds
CN103987723B (en) 2011-12-16 2017-03-01 弗·哈夫曼-拉罗切有限公司 The inhibitor of HCV NS5A
LT2794628T (en) 2011-12-20 2017-07-10 Riboscience Llc 4`-azido-3`-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
US9108999B2 (en) 2011-12-20 2015-08-18 Riboscience Llc 2′, 4′-difluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
JP6092261B2 (en) 2012-02-24 2017-03-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Antiviral compounds
EP2828249B1 (en) 2012-03-23 2018-10-10 The Regents of The University of California Premature-termination-codons readthrough compounds
EP2838614B1 (en) 2012-04-20 2019-09-11 GB006, Inc. Compositions for regulating integrins
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
CA2892589A1 (en) 2013-01-23 2014-07-31 F. Hoffmann-La Roche Ag Antiviral triazole derivatives
CN105008350B (en) 2013-03-05 2018-05-08 弗·哈夫曼-拉罗切有限公司 Antiviral compound
RU2534613C2 (en) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Alkyl2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2h-pyrimidine-1-yl)- -hydroxy- tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-proptonates, nucleoside inhibitors of rna-polymerase hcv ns5b, methods for producing and using them
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
BR112015028764B1 (en) 2013-05-16 2022-09-27 Riboscience Llc SUBSTITUTED 4-FLUORO-2-METHYL NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
MA38678A1 (en) 2013-05-16 2017-07-31 Riboscience Llc Nucleoside derivatives 4'-azido, 3'-deoxy-3'-fluoro substituted
AR112702A1 (en) 2017-09-21 2019-11-27 Riboscience Llc 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS HCV RNA REPLICATION INHIBITORS
KR101893988B1 (en) * 2018-05-16 2018-08-31 (주)에빅스젠 Pharmaceutical composition comprising Rhodanine derivative for preventing or treating AIDS
WO2023161427A1 (en) 2022-02-24 2023-08-31 Eisbach Bio Gmbh Viral combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909467A (en) * 1958-07-09 1959-10-20 Us Vitamin Pharm Corp 3-(d-alpha-methylphenethyl)-5-methyl-1, 3-oxazolidine-2, 4-dione
US3888984A (en) * 1972-03-13 1975-06-10 Lilly Industries Ltd Oxazole and imidazole derivatives as antifungal agents
AU6610081A (en) * 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
US4367234A (en) * 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
CA2134877A1 (en) * 1992-05-01 1993-11-11 Helmut Weigold Heteropolytungstates in the treatment of flavivirus infection
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
DE19645974C1 (en) * 1996-11-07 1998-08-13 Andreas Johannes Kesel (Z) -5 - [[3-Hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone, process for its preparation and use

Also Published As

Publication number Publication date
WO2000010573A1 (en) 2000-03-02
EP1128832A4 (en) 2003-03-05
KR20010099623A (en) 2001-11-09
EP1128832A1 (en) 2001-09-05
CN1325309A (en) 2001-12-05
JP2002523371A (en) 2002-07-30
CA2341970A1 (en) 2000-03-02
IL141456A0 (en) 2002-03-10
BR9913157A (en) 2001-05-15
AU743411B2 (en) 2002-01-24
AU5570299A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
ID27787A (en) COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES
ID21526A (en) 4-HYDROXYQUINOLIN-3-CARBOXOXIDE AND HYDRAZIDE AS ANTI-VIRUS INGREDIENTS
BR0309581A (en) Nucleoside derivatives for treatment of hepatitis c virus infection
ID27457A (en) COMPOSITION FOR HIV TREATMENT AND OTHER VIRUS INFECTIONS
BR9908004A (en) Compound, composition and method for preventing or suppressing a viral infection
WO2003053349A3 (en) Inhibitors of hepatitis c virus
EA200201263A1 (en) METHODS OF TREATING INFECTIONS, CAUSED BY THE HEPATITIS DELTA VIRUS, USING β-L-2'-DEOXYNUCLEOSIDES
UY35542A (en) METHODS AND COMPOSITIONS TO TREAT HEPATITIS C VIRUS
EA200400022A1 (en) CONNECTIONS AND METHODS OF TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
WO2007076034A3 (en) Anti-viral compounds
WO2007081517A3 (en) Anti-viral compounds
WO2007076035A3 (en) Anti-viral compounds
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
ATE295355T1 (en) TRIS-SUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS
EA200500723A1 (en) COMPOUNDS OF BENZOFURANE, COMPOSITIONS AND METHODS OF TREATMENT AND PREVENTION OF INFECTIONS, CAUSED BY THE HEPATITIS C VIRUS, AND RELATED DISEASES
WO1999052515A3 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections
NO20052580D0 (en) Compounds for the treatment of infection by Flavivirida viruses
ATE231839T1 (en) POLYAROMATIC ANTIVIRAL COMPOSITIONS
PT1299395E (en) OXAZINOQUINOLONES UTEIS FOR THE TREATMENT OF INFECTIONS CAUSED BY VIRUSES
NZ505894A (en) Methylenebisbenzaldehyde derivatives, methylidynetrisphenol derivative and pharmaceuticals thereof; useful for treating or preventing pneumovirus infection and associated diseases
WO2001097824A3 (en) Use of phyllanthus constituents for treating or preventing infections caused by flaviviridae
WO2003049674A3 (en) Method for treatment of enveloped viruses using jojoba oil esters
ATE253578T1 (en) OXAZINOQUINOLONES FOR THE TREATMENT OF VIRAL INFECTIONS
ATE493408T1 (en) ANTINIFECTIVE AGENTS
FI965114A0 (en) Pharmaceutical composition for the prevention and / or treatment of viral infections and, optionally, inflammation and method of their treatment